Langhorne, PA (PRWEB) September 01, 2011
EUSA Pharma (USA), Inc. is pleased to have launched the new Caphosol® (supersaturated calcium phosphate rinse) website (http://www.caphosol.com) developed with the goal of providing a comprehensive resource on oral mucositis to both patients and healthcare professionals. The site also contains the key information required to understand how Caphosol can help in dealing with the debilitating effects of oral mucositis.
The website is simple to use and allows easy navigation for visitors enabling them to find a wealth of information about Oral Mucositis and Caphosol.
Oral mucositis is a painful side effect of cancer therapy and is typically characterized by a red, swollen and ulcerated mouth and tongue. This painful condition, associated with both chemotherapy and radiation, can prevent patients from talking and even from eating or drinking. In a survey of 558 nurses undertaken at the Annual Oncology Nursing Society Congress, Oral Mucositis was identified as the most debilitating problem associated with cancer therapy.¹
Caphosol® is a supersaturated calcium phosphate mouth rinse indicated for dryness of the mouth and oropharynx (hyposalivation, xerostomia), regardless of the cause and regardless of whether the condition is temporary or permanent. Caphosol is also indicated as an adjunct to standard oral care for treatment of the mucositis that may be caused by radiation or high dose chemotherapy. Relief of dryness of the oral mucosa in these conditions is associated with amelioration of pain.²
- Reported side effects have been rare and generally mild
- Special precautions for use: Contains sodium (71 mg per 30mL dose). Patients restricted to a low sodium diet should consult their physician before use.
- If Caphosol is swallowed accidentally, no adverse affects are expected
- There are no known interactions with other medicines
About EUSA Pharma
EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care products. The company has an established commercial infrastructure in the U.S., a pan-European presence and a wider distribution network in numerous additional territories. EUSA Pharma currently has a total of 10 specialist hospital products, which are sold in over 80 countries globally*. For further information on EUSA Pharma or the product portfolio please visit http://www.eusapharma.com.
1. Bruce SD and Quinn A. US Oncological Disease 2007;1:86-90
2. Caphosol® (supersaturated calcium phosphate rinse) Prescribing Information. July 2009
- Not all are approved for use in the U.S.
EUSAPharma (USA), Inc.
One Summit Square
1717 Langhorne-Newtown Road
Langhorne, PA 19047